Literature DB >> 25004214

Sanofi's dengue vaccine first to complete phase 3.

Gunjan Sinha.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25004214     DOI： 10.1038/nbt0714-605a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Science snipes at Oxitec transgenic-mosquito trial.

Authors:  Nidhi Subbaraman
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908

Review 2.  From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Authors:  Bruno Guy; Beatrice Barrere; Claire Malinowski; Melanie Saville; Remy Teyssou; Jean Lang
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

3.  The global distribution and burden of dengue.

Authors:  Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962
  3 in total
  10 in total

1.  Mexico dengue vaccine first.

Authors: 
Journal:  Nat Biotechnol       Date:  2016-01       Impact factor: 54.908

Review 2.  Current neurological observations and complications of dengue virus infection.

Authors:  Marylou V Solbrig; Guey-Chuen Perng
Journal:  Curr Neurol Neurosci Rep       Date:  2015-06       Impact factor: 5.081

3.  Incidence and Clinical Outcome of Acute Liver Failure Caused by Dengue in a Hospital for Tropical Diseases, Thailand.

Authors:  Khin Kye Mon; Apichart Nontprasert; Chatporn Kittitrakul; Pisit Tangkijvanich; Wattana Leowattana; Kittiyod Poovorawan
Journal:  Am J Trop Med Hyg       Date:  2016-10-17       Impact factor: 2.345

4.  NIH dengue vaccine leaps into phase 3 studies.

Authors:  Jeffrey M Perkel
Journal:  Nat Biotechnol       Date:  2016-05-06       Impact factor: 54.908

5.  The contribution of non-human primate models to the development of human vaccines.

Authors:  Tania Rivera-Hernandez; Diane G Carnathan; Peter M Moyle; Istvan Toth; Nicholas P West; Paul R Young; Guido Silvestri; Mark J Walker
Journal:  Discov Med       Date:  2014-12       Impact factor: 2.970

Review 6.  Recent progress in dengue vaccine development.

Authors:  Jianchun Wei; Hui Chen; Jing An
Journal:  Virol Sin       Date:  2014-12-24       Impact factor: 4.327

7.  Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearance.

Authors:  Alan Yi-Hui Hsu; Shang-Rung Wu; Jih-Jin Tsai; Po-Lin Chen; Ya-Ping Chen; Tsai-Yun Chen; Yu-Chih Lo; Tzu-Chuan Ho; Meed Lee; Min-Ting Chen; Yen-Chi Chiu; Guey Chuen Perng
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

8.  Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis.

Authors:  Bruno Rodrigues Rosa; Antonio José Ledo Alves da Cunha; Roberto de Andrade Medronho
Journal:  BMJ Open       Date:  2019-03-13       Impact factor: 2.692

9.  Expansion of highly activated invariant natural killer T cells with altered phenotype in acute dengue infection.

Authors:  A Kamaladasa; N Wickramasinghe; T N Adikari; L Gomes; N L A Shyamali; M Salio; V Cerundolo; G S Ogg; G Neelika Malavige
Journal:  Clin Exp Immunol       Date:  2016-08       Impact factor: 4.330

Review 10.  Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents.

Authors:  Stephen J Streatfield; Natasha Kushnir; Vidadi Yusibov
Journal:  Plant Biotechnol J       Date:  2015-10       Impact factor: 9.803
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.